Sukumar Pal

picture of Sukumar  Pal

Project Scientist, Pathology
School of Medicine


Ph.D., University of Calcutta, 1988, Zoology (Parasitic Immunology)
Administrative management, University of California, Irvine, 2002

Phone: (949) 824-7450, (949) 293-7541 (cell)
Fax: (949) 824-2160
Email: spal@uci.edu

University of California, Irvine
D440 Medical Sciences 1
Room no. D440
Mail Code: 4800
Irvine, CA 92697
Research Interests
Vaccine Development for Chlamydial infections
Academic Distinctions
-1989, Fight for Sight Research Fellowship Award

- 1992, Vector Laboratories Young Investigator Award

-1995, Career Development Award, University of California, Irvine

-2005, Who's Who in America
Appointments
- Johns Hopkins University, Baltimore, Maryland
- University of California, Irvine, California
Research Abstract
Of all sexually transmitted bacterial diseases, Chlamydia trachomatis infections are the most common ones in all nations of the world. Most pregnant women infected with C. trachomatis transmit infections to their neonates at birth. Neonatal chlamydial infections include inclusion conjunctivitis and pneumonia. In the U.S., the rate of neonatal infection is 8.2 per 1,000 live births. These infections are associated with a high incidence of morbidity and economic loss, but if diagnosed in time, can be treated with antibiotics. However, the use of antibiotics creates several potential problems, including compliance with medicine regimens, development of persistent infections, emergence of antibiotic- resistant strains, and drug allergies. In addition, antibiotic treatment has been associated with enhanced susceptibility to reinfection at the population level. Therefore, development of a therapeutic vaccine or treatment for neonatal infections may be an effective way to counteract these problems. Because we currently lack an appropriate animal model, knowledge of C. trachomatis infections during the neonatal period is limited. Recently, our laboratory developed a neonatal mouse model of the C. trachomatis infection using the C. trachomatis mouse pneumonitis biovar (MoPn). In this model, newborn pups born to previously MoPn-infected dams are inoculated intranasally at 48 hours of age. Pups then are euthanized at various days post-inoculation to monitor bacterial burden in their lungs. This study's overall aim is to identify a Th1 immune component in mediating a C. trachomatis infection in neonates. More specifically, the research will investigate the role of Th1 immunity in resolving C. trachomatis infections during the neonatal period. This study's hypothesis is that a Th1- mediated immunity is needed to resolve a C. trachomatis infection in neonatal life. To test the hypothesis, newborn pups will receive MoPn-specific T-cells, or Th1-modulating/mediating
cytokines, and an intranasal infection will be used to evaluate the efficacy of the adoptive immunity. We predict that neonates with added Th1 immunity will clear C. trachomatis infections more effectively than the non-recipient neonates. The study's result will help us to develop a therapeutic neonatal vaccine against C. trachomatis infections.
PUBLIC HEALTH RELEVANCE: Chlamydia trachomatis infections are a major health problem in both developed and underdeveloped countries. The goal of this proposal is to develop a vaccine for the newborn babies who are born from Chlamydia infected mothers. Decreasing the incidence and prevalence of these infections with a vaccine will have a major health impact worldwide.
Publications
List of Publications 101 citations, (newest to oldest)



1. Tifrea DF, Pal S, de la Maza LM. A recombinant Chlamydia trachomatis MOMP vaccine elicits cross-serogroup protection in mice against vaginal shedding and infertility. J Infect Dis. 2019 Aug 28; doi: 10.1093/infdis/jiz438. [Epub ahead of print] PubMed PMID: 31504647.

2. Pal S, Tifrea DF, de la Maza LM. Characterization of the Horizontal and Vertical Sexual Transmission of Chlamydia Genital Infections in a New Mouse Model. Infect Immun. 2019 Jul; 87 (7). doi: 10.1128/IAI.00834-18. Print 2019 Jul. PubMed PMID: 30833332; PubMed Central PMCID: PMC6589058.

3. Tifrea DF, Pal S, Le Bon C, Giusti F, Popot JL, Cocco MJ, Zoonens M, de la Maza LM. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia. Vaccine. 2018 Oct 29; 36 (45): 6640-6649. doi: 10.1016/j.vaccine.2018.09.055. Epub 2018 Oct 4. PubMed PMID: 30293763.

4. Pal S, Tifrea DF, Zhong G, de la Maza LM. Transcervical Inoculation with Chlamydia trachomatis Induces Infertility in HLA-DR4 Transgenic and Wild-Type Mice. Infect Immun. 2018 Jan; 86 (1). doi: 10.1128/IAI.00722-17. Print 2018 Jan. PubMed PMID: 29038126; PubMed Central PMCID: PMC5736824.

5. Pal S, Tifrea DF, de la Maza LM. Implementation of a new murine model for the characterization of the horizontal and vertical transmission of genital chlamydial infections. In Proceedings of the fourteenth international symposium on human chlamydial infections, Ziest, Netherland. 2018: 211-214.

6. Pal S, Favaroni A, Tifrea DF, Hanisch PT, Luczak SET, Hegemann JH, de la Maza LM. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge. Vaccine. 2017 May 2;35(19):2543-2549. doi: 10.1016/j.vaccine.2017.03.070. Epub 2017 Apr 3. PubMed PMID: 28385608; PubMed Central PMCID: PMC5464790.

7. Pal S, Tifrea DF, Follmann F, Andersen P, de la Maza LM. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine. 2017 Mar 23; 35 (13): 1705-1711. doi: 10.1016/j.vaccine.2017.02.020. Epub 2017 Feb 24. PubMed PMID: 28238632.

8. Tifrea DF, Barta ML, Pal S, Hefty PS, de la Maza LM. Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen. Microbes Infect. 2016 Apr; 18 (4): 245-53. doi: 10.1016/j.micinf.2015.12.002. Epub 2015 Dec 17. PubMed PMID: 26706820.

9. Pal S, Tatarenkova OV, de la Maza LM. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology. 2015 Nov; 146 (3): 432-43. doi: 10.1111/imm.12520. Epub 2015 Oct 1. PubMed PMID: 26423798; PubMed Central PMCID: PMC4610632.

10. Tifrea DF, Pal S, Popot JL, Cocco MJ, de la Maza LM. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J Immunol. 2014 Jun 1; 192 (11): 5201-13. doi: 10.4049/jimmunol.1303392. Epub 2014 Apr 28. PubMed PMID: 24778450; PubMed Central PMCID: PMC4030638.

11. Al-Kuhlani M, Rothschild J, Pal S, de la Maza LM, Ouburg S, Morré SA, Dean D, Ojcius DM. TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans. PLoS One. 2014; 9 (4): e93939. doi: 10.1371/journal.pone.0093939. eCollection 2014. PubMed PMID: 24695582; PubMed Central PMCID: PMC3973638.

12. Cheng C, Pal S, Tifrea D, Jia Z, de la Maza LM. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect. 2014 Mar; 16 (3): 244-52. doi: 10.1016/j.micinf.2013.11.009. Epub 2013 Nov 27. PubMed PMID: 24291713; PubMed Central PMCID: PMC3965591.

13. Cheng C, Jain P, Pal S, Tifrea D, Sun G, Teng AA, Liang X, Felgner PL, de la Maza LM. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). Microbes Infect. 2014 Feb; 16 (2): 123-133. doi: 10.1016/j.micinf.2013.10.012. Epub 2013 Oct 23. PubMed PMID: 24161793; PubMed Central PMCID: PMC3946604.

14. Pal S, Tifrea DF, Cheng CC, de la Maza LM. Characterization of the immune responses during the acute stage of a Chlamydia muridarum respiratory infection in naive and vaccinated mice. In Proceedings of the thirteenth international symposium on human chlamydial infections, Pacific Grove, CA, USA. 2014: 303-6.

15. Tifrea DF, Pal S, Toussi DN, Massari P, de la Maza LM. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge. Microbes Infect. 2013 Nov; 15 (13): 920-7. doi: 10.1016/j.micinf.2013.08.005. Epub 2013 Aug 30. PubMed PMID: 23999313; PubMed Central PMCID: PMC3842390.

16. Pal S, de la Maza LM. Mechanism of T-cell mediated protection in newborn mice against a Chlamydia infection. Microbes Infect. 2013 Jul-Aug; 15 (8-9): 607-14. doi: 10.1016/j.micinf.2013.04.010. Epub 2013 May 2. PubMed PMID: 23644176; PubMed Central PMCID: PMC5058356.

17. Tifrea DF, Ralli-Jain P, Pal S, de la Maza LM. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun. 2013 May; 81 (5):1741-50. doi: 10.1128/IAI.00734-12. Epub 2013 Mar 11. PubMed PMID: 23478318; PubMed Central PMCID: PMC3648024.

18. Carmichael JR, Tifrea D, Pal S, de la Maza LM. Differences in infectivity and induction of infertility: a comparative study of Chlamydia trachomatis strains in the murine model. Microbes Infect. 2013 Mar; 15 (3):219-29. doi: 10.1016/j.micinf.2012.12.001. Epub 2012 Dec 31. PubMed PMID: 23287699; PubMed Central PMCID: PMC3602122.

19. Teng A, Cruz-Fisher MI, Cheng C, Pal S, Sun G, Ralli-Jain P, Molina DM, Felgner PL, Liang X, de la Maza LM. Proteomic identification of immunodominant chlamydial antigens in a mouse model. J Proteomics. 2012 Dec 21; 77: 176-86. doi: 10.1016/j.jprot.2012.08.017. Epub 2012 Aug 31. PubMed PMID: 22959960; PubMed Central PMCID: PMC3575745.

20. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine. 2011 Sep 2; 29 (38): 6641-9. doi: 10.1016/j.vaccine.2011.06.105. Epub 2011 Jul 8. PubMed PMID: 21742006; PubMed Central PMCID: PMC3156873.

21. Carmichael JR, Pal S, Tifrea D, de la Maza LM. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine. 2011 Jul 18; 29 (32): 5276-83. doi: 10.1016/j.vaccine.2011.05.013. Epub 2011 May 24. PubMed PMID: 21609745; PubMed Central PMCID: PMC3139009.

22. Tifrea DF, Sun G, Pal S, Zardeneta G, Cocco MJ, Popot JL, de la Maza LM. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine. 2011 Jun 20; 29 (28): 4623-31. doi: 10.1016/j.vaccine.2011.04.065. Epub 2011 May 6. PubMed PMID: 21550371; PubMed Central PMCID: PMC3114171.

23. Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine. 2011 Apr 18; 29 (18): 3456-64. doi: 10.1016/j.vaccine.2011.02.057. Epub 2011 Mar 4. PubMed PMID: 21376796; PubMed Central PMCID: PMC3084512.

24. Cheng C, Cruz-Fisher MI, Tifrea D, Pal S, Wizel B, de la Maza LM. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®. Vaccine.2011 Mar 16; 29 (13): 2437-43. doi: 10.1016/j.vaccine.2011.01.031. Epub 2011 Jan 26. PubMed PMID: 21276442.

25. Cruz-Fisher MI, Cheng C, Sun G, Pal S, Teng A, Molina DM, Kayala MA, Vigil A, Baldi P, Felgner PL, Liang X, de la Maza LM.Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect Immun. 2011 Jan; 79 (1): 246-57. doi: 10.1128/IAI.00626-10. Epub 2010 Oct 18. PubMed PMID: 20956570; PubMed Central PMCID: PMC3019893.

26. Pal S. Vaccines against genital infections with Chlamydia. In Vaccine against bacterial biothreat pathogens, eds V A Feodorova, V L Motin, Research Signpost, India. 2011:111-27.

27. Pal S, Sarcon AK, de la Maza LM. A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males. Vaccine. 2010 Nov 10; 28 (48): 7606-12. doi: 10.1016/j.vaccine.2010.09.060. Epub 2010 Oct 13. PubMed PMID: 20920574; PubMed Central PMCID: PMC2981627.

28. Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza LM. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine. 2010 Nov 10; 28 (48): 7659-66. doi: 10.1016/j.vaccine.2010.09.040. Epub 2010 Sep 25. PubMed PMID: 20875490; PubMed Central PMCID: PMC2981640.

29. Pal S, Tatarenkova O, de la Maza LM. Maternal immunity partially protects newborn mice against a Chlamydia trachomatis intranasal challenge. J Reprod Immunol. 2010 Nov; 86 (2): 151-7. doi: 10.1016/j.jri.2010.04.003. Epub 2010 Jun 15. PubMed PMID: 20554327; PubMed Central PMCID: PMC2949516.

30. Molina DM, Pal S, Kayala MA, Teng A, Kim PJ, Baldi P, Felgner PL, Liang X, de la Maza LM. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine. 2010 Apr 9; 28 (17): 3014-24. doi: 10.1016/j.vaccine.2009.12.020. Epub 2009 Dec 29. PubMed PMID: 20044059; PubMed Central PMCID: PMC3048468.

31. Pal S, Sarcon AK, de la Maza LM. C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis. Infect Immun. 2009 Dec; 77 (12): 5602-7. doi: 10.1128/IAI.00766-09. Epub 2009 Oct 5. PubMed PMID: 19805533; PubMed Central PMCID: PMC2786464.

32. Cheng C, Bettahi I, Cruz-Fisher MI, Pal S, Jain P, Jia Z, Holmgren J, Harandi AM, de la Maza LM. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine. 2009 Oct 19; 27 (44): 6239-46. doi: 10.1016/j.vaccine.2009.07.108. Epub 2009 Aug 15. PubMed PMID: 19686693; PubMed Central PMCID: PMC3566636.

33. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009 Aug 6; 27 (36): 5020-5. doi: 10.1016/j.vaccine.2009.05.008. Epub 2009 May 27. PubMed PMID: 19446590; PubMed Central PMCID: PMC2741729.

34. Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, Peterson EM, Pal S, de la Maza LM, Caldwell HD. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol. 2009 Jun 15; 182 (12): 8063-70. doi: 10.4049/jimmunol.0804375. PubMed PMID: 19494332; PubMed Central PMCID: PMC2692073.

35. Pal S, Bravo J, Peterson EM, de la Maza LM. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun. 2008 Dec; 76(12): 5581-7. doi: 10.1128/IAI.00574-08. Epub 2008 Sep 22. PubMed PMID: 18809664; PubMed Central PMCID: PMC2583570.

36. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29 (4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2. PubMed PMID: 18835197; PubMed Central PMCID: PMC2732399.

37. Sun G, Pal S, Sarcon AK, Kim S, Sugawara E, Nikaido H, Cocco MJ, Peterson EM, de la Maza LM. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol. 2007 Sep; 189(17): 6222-35. doi: 10.1128/JB.00552-07. Epub 2007 Jun 29. PubMed PMID: 17601785; PubMed Central PMCID: PMC1951919.

38. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2006 Feb 6; 24 (6):766-75. doi: 10.1016/j.vaccine.2005.08.074. Epub 2005 Sep 6. PubMed PMID: 16199110.

39. Pal S, Schmidt AP, Peterson EM, Wilson CL, de la Maza LM. Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection. Immunology. 2006 Feb; 117 (2): 213-9. doi: 10.1111/j.1365-2567.2005.02281.x. PubMed PMID: 16423057; PubMed Central PMCID: PMC1782213.

40. de la Maza LM, Pole JC, Sarcon AK, Pal S, Li D, Procaccio V, Wallace D. Dependence of Chlamydia on the host cell mitochondrial DNA for growth and maturation. In Proceedings of the Eleventh International Symposium on Human Chlamydial Infections. 2006; 261-64.

41. Pal S, Sarcon AK, Peterson EM, de la Maza LM. Infection of male mice in the genitourinary tract with Chlamydia trachomatis serovar D. In Proceedings of the Eleventh International Symposium on Human Chlamydial Infections. 2006; 429-432.

42. Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005 Dec; 73 (12): 8153-60. doi: 10.1128/IAI.73.12.8153-8160.2005. PubMed PMID: 16299310; PubMed Central PMCID: PMC1307068.

43. Pal S, Peterson EM, de la Maza LM. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. Vaccine. 2005 Nov 16; 23 (46-47): 5351-8. doi: 10.1016/j.vaccine.2005.06.026. Epub 2005 Jul 19. PubMed PMID: 16085340.

44. Yen TY, Pal S, de la Maza LM. Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry. 2005 Apr 26; 44 (16): 6250-6. doi: 10.1021/bi047775v. PubMed PMID: 15835913.

45. Pal S, Peterson EM, de la Maza LM. New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males. Infect Immun. 2004 Jul; 72 (7): 4210-6. doi: 10.1128/IAI.72.7.4210-4216.2004. PubMed PMID: 15213165; PubMed Central PMCID: PMC427456.

46. Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can induce protection against genital challenge. In Proceedings of 5th meeting of the European Society for Chlamydia Research, Ed J. Deak. University of Szeged, Budapest, Hungary.. 2004;

47. Pal S, Peterson EM, de la Maza LM. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology. 2003 Nov; 110 (3): 368-75. doi: 10.1046/j.1365-2567.2003.01748.x. PubMed PMID: 14632665; PubMed Central PMCID: PMC1783049.

48. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine. 2003 Mar 28; 21(13-14): 1455-65. doi: 10.1016/s0264-410x(02)00680-1. PubMed PMID: 12615442.

49. Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002 Sep; 70 (9): 4812-7. doi: 10.1128/iai.70.9.4812-4817.2002. PubMed PMID: 12183524; PubMed Central PMCID: PMC128273.

50. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001 Oct; 69 (10): 6240-7. doi: 10.1128/IAI.69.10.6240-6247.2001. PubMed PMID: 11553566; PubMed Central PMCID: PMC98757.

51. Pal S, Peterson EM, de la Maza LM. Susceptibility of mice to vaginal infection with Chlamydia trachomatis mouse pneumonitis is dependent on the age of the animal. Infect Immun. 2001 Aug; 69 (8): 5203-6. doi: 10.1128/IAI.69.8.5203-5206.2001. PubMed PMID: 11447208; PubMed Central PMCID: PMC98622.

52. Pal S, Peterson EM, de La Maza LM. Role of Nramp1 deletion in Chlamydia infection in mice. Infect Immun. 2000 Aug; 68 (8): 4831-3. doi: 10.1128/iai.68.8.4831-4833.2000. PubMed PMID: 10899900; PubMed Central PMCID: PMC98449.

53. Pal S, Rangel J, Peterson EM, de la Maza LM. Immunogenic and protective ability of the two developmental forms of Chlamydiae in a mouse model of infertility. Vaccine. 1999 Nov 12; 18 (7-8): 752-61. doi: 10.1016/s0264-410x(99)00032-8. PubMed PMID: 10547436.

54. Pal S, Peterson EM, De La Maza LM. A murine model for the study of Chlamydia trachomatis genital infections during pregnancy. Infect Immun. 1999 May; 67 (5): 2607-10. PubMed PMID: 10225927; PubMed Central PMCID: PMC116010.

55. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 1999 Feb 26; 283 (5406): 1335-9. doi: 10.1126/science.283.5406.1335. PubMed PMID: 10037605.

56. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, de la Maza LM. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine. 1999 Feb 5;17(5):459-65. doi: 10.1016/s0264-410x(98)00219-9. PubMed PMID: 10073724.

57. Pal S, Hui W, Peterson EM, de la Maza LM. Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. J Med Microbiol. 1998 Jul; 47 (7): 599-605. doi: 10.1099/00222615-47-7-599. PubMed PMID: 9839564.

58. Pal S, Peterson EM, de la Maza LM. Characterization of the immunogenic and protective ability of two developmental-forms of Chlamydia trachomatis. In Proceedings of the ninth International Symposium on Human Chlamydial Infection. R.S. Stephens et al (eds.) International Chlamydial Symposium, San Francisco, U.S.A. Napa, California, U.S.A. 1998; 450-53.

59. Pal S, Barnhart KM, Abai AM, Peterson EM, de la Maza LM. Immunization of mice with expression plasmids containing DNA sequences corresponding to the C. trachomatis MoPn MOMP failed to protect against a genital challenge. In Proceedings of the ninth International Symposium on Human Chlamydial Infection. R.S. Stephens et al (eds.) International Chlamydial Symposium, San Francisco, U.S.A. Napa, California, U.S.A. 1998; 438-41.

60. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun. 1997 Aug; 65(8): 3361-9. PubMed PMID: 9234798; PubMed Central PMCID: PMC175475.

61. Pal S, Theodor I, Peterson EM, de la Maza LM. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge.Vaccine. 1997 Apr; 15 (5): 575-82. doi: 10.1016/s0264-410x(97)00206-5. PubMed PMID: 9160528.

62. Pal S, Peterson EM, de la Maza LM. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun. 1996 Dec; 64 (12): 5341-8. PubMed PMID: 8945586; PubMed Central PMCID: PMC174528.

63. Pal S, Sengupta K, Manna B, Sarkar S, Bhattacharya S, Das P. Comparative evaluation of somatic & excretory-secretory antigens of Entamoeba histolytica in serodiagnosis of human amoebiasis by ELISA. Indian J Med Res. 1996 Jul; 104: 152-6. PubMed PMID: 8783520.

64. Pal S, Sengupta K, Manna B, Sarkar S, Bhattacharya SK, Das P. Comparative Evaluation of somatic and excretory-secretory antigens of Entamoeba histolytica in serodiagnosis of human amoebiasis by enzyme linked immunosorbent assay. Indian J. of Medical Research. 1996; 104:152-56.

65. Campos M, Pal S, O'Brien TP, Taylor HR, Prendergast RA, Whittum-Hudson JA. A chlamydial major outer membrane protein extract as a trachoma vaccine candidate. Invest Ophthalmol Vis Sci. 1995 Jul; 36 (8): 1477-91. PubMed PMID: 7601629.

66. Campus M, O'Brien TP, Pal S, Taylor HR, Prendergast RA, Whittum-Hudson JA. An extract of the major outer membrane protein of Chlamydia trachomatis as trachoma vaccine candidate. Invest. Ophthal. Vis. Sci. 1995; 36:1477-91.

67. Pal S, Fielder TJ, Peterson EM, de la Maza LM. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun. 1994 Aug; 62 (8): 3354-62. PubMed PMID: 8039906; PubMed Central PMCID: PMC302966.

68. Khamesipour A, Pal S, Peterson EM, de la Maza LM. Induction of infertility by the Chlamydia trachomatis mouse pneumonitis biovar in strains of mice that differ in their response to the 60 kDa heat shock protein. J Reprod Fertil. 1994 Jul; 101 (2): 287-94. doi: 10.1530/jrf.0.1010287. PubMed PMID: 7932361.

69. de la Maza LM, Pal S, Khamesipour A, Peterson EM. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun. 1994 May; 62 (5): 2094-7. PubMed PMID: 8168974; PubMed Central PMCID: PMC186471.

70. Pal S, Theodore I, Peterson EM, de la Maza LM. Characterization of a neutralizing IgA monoclonal antibody directed against the Chlamydia trachomatis mouse pneumonitis biovar. In Proceedings of the 8th International Symposium on Human Chlamydial Infection, Eds J. Orfila et al. Società Esculapio, Italy. 1994; 141-144.

71. de la Maza LM, Pal S, Khamesipour A, Peterson EM. Intravaginal inoculation of Mice with the Chlamydia trachomatis mouse pneumonitis biovar results infertility. In Proceedings of the 8th International Symposium on Human Chlamydial Infection, Eds J. Orfila et al; (eds.). Società Esculapio, Italy. 1994; 537-540.

72. Pal S, Cheng X, Peterson EM, de la Maza LM. Mapping of a surface-exposed B-cell epitope to the variable sequent 3 of the major outer-membrane protein of Chlamydia trachomatis. J Gen Microbiol. 1993 Jul; 139 (7): 1565-70. doi: 10.1099/00221287-139-7-1565. PubMed PMID: 7690394.

73. Peterson EM, Cheng X, Pal S, de la Maza LM. Effects of antibody isotype and host cell type on in vitro neutralization of Chlamydia trachomatis. Infect Immun. 1993 Feb; 61(2): 498-503. PubMed PMID: 8423079; PubMed Central PMCID: PMC302756.

74. Pal S, Fielder TJ, Peterson EM, de la Maza LM. Analysis of the immune response in mice following intrauterine infection with the Chlamydia trachomatis mouse pneumonitis biovar. Infect Immun. 1993 Feb;61(2):772-6. PubMed PMID: 8423104; PubMed Central PMCID: PMC302793.

75. Das P, Sengupta K, Pal S, Das D, Pal SC. Biochemical and immunological studies on soluble antigens of Entamoeba histolytica. Parasitol Res. 1993; 79 (5): 365-71. doi: 10.1007/bf00931824. PubMed PMID: 8415541.

76. Pal S, Taylor HR, Huneke RB, Prendergast RA, Whittum-Hudson JA. Frequency of antigen-specific B cells during experimental ocular Chlamydia trachomatis infection. Infect Immun. 1992 Dec; 60(12):5294-7. PubMed PMID: 1452363; PubMed Central PMCID: PMC258309.

77. Cheng X, Pal S, de la Maza LM, Peterson EM. Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E. Infect Immun. 1992 Aug; 60(8): 3428-32. PubMed PMID: 1639510; PubMed Central PMCID: PMC257331.

78. O'Brien TP, Prendergast RA, Campos M, Pal S, Taylor HR, Whittum-Hudson JA. Protective immunity induction by an anti-Chlamydial vaccine. Invest. Ophthalmol. Vis. Sci. 1992; 33 (Suppl): 848.

79. Pal S, Fielder TJ, Peterson EM, de la Maza LM. Intranasal immunization protects BALB/c mice against an intrauterine challenge with Chlamydia trachomatis MoPn. In European Society for Chlamydia Research, Eds P.A. Mardh, M. La Placa, M. Ward. University of Uppsala, Uppsala, Stockholm, Sweden. 1992; 106.

80. Peterson EM, Horansky M, Cheng X, Pal S, Qu Z, de la Maza LM. . In vitro neutralization of Chlamydia trachomatis using combination of monoclonal antibodies directed at the major outer membrane protein (MOMP). In Proceedings of the European Society for Chlamydia Research and the 2nd international symposium of Uppsala University center for STD Research. Eds P.A. Mardh, M. La Placa, M. Ward, University of Uppsala. 1992; 61.

81. Fielder TJ, Pal S, Peterson EM, de la Maza LM. Sequence of the gene encoding the major outer membrane protein of the mouse pneumonitis biovar of Chlamydia trachomatis. Gene. 1991 Sep 30; 106 (1):137-8. doi: 10.1016/0378-1119(91)90579-z. PubMed PMID: 1937036.

82. Pal S, Zhang P, Hunekee H, Taylor HR, Whittum-Hudson JA. Evidence for a high frequency of Chlamydia-specific lymphocytes in conjunctiva during ocular infection. Regional Immunology. 1991; 3:171-176.

83. Taylor HR, Maclean IW, Brunham RC, Pal S, Whittum-Hudson J. Chlamydial heat shock proteins and trachoma. Infect Immun. 1990 Sep;58 (9):3061-3. PubMed PMID: 2387634; PubMed Central PMCID: PMC313611.

84. Pal S, Pu Z, Huneke RB, Taylor HR, Whittum-Hudson JA. Chlamydia-specific lymphocytes in conjunctiva during ocular infection: limiting dilution analysis. Reg Immunol. 1990-1991; 3 (4): 171-6. PubMed PMID: 1716948.

85. Pal S, Taylor HR, Whittum-Hudson JA. Longitudinal changes in antigen specific antibody responses in a model of trachoma. The FASEB J. 1990; 4(3): A766.

86. Pal S, Taylor HR, Whittum-Hudson JA. Identification of fine antigenic specificities of antibody responses in experimental Chlamydia trachomatis infection. Invest. Opththalmol Vis. Sci. 1990; 31(4): 448.

87. Whittum-Hudson JA, Pal S, Zhang P, Taylor HR. In vitro functional studies of conjunctival lymphocytes after ocular Chlamydia trachomatis infection. In Advances in Mucosal Immunology, Proceedings of the 5th International Congress of Mucosal Immunology, T. McDonald et al., (eds.). Kluwer Academic Publishers, Lancaster, U. K. 1990; 526-529.

88. Whittum-Hudson JA, Zhang P, Pal S, Taylor HR. Chlamydia-specific lymphocytes in conjunctiva in a model of trachoma. In Proceedings of the 7th International Symposium on Human Chlamydial Infection. W. R. Bowie et al., (eds.). Cambridge University Press, N. Y. U.S.A. 1990; 287-290.

89. Whittum-Hudson JA, Pal S, Zhang P, Taylor HR. In vitro functional studies of conjunctival lymphocytes after ocular Chlamydia trachomatis infection. In Advances in Mucosal Immunology, Proceedings of the 5th International Congress of Mucosal Immunology, T. McDonald et al., (eds.). Kluwer Academic Publishers, Lancaster, U. K. 1990; 526-529.

90. Pal S, Bhattacharya SK, Das P, Chaudhuri P, Dutta P, De SP, Sen D, Saha MR, Nair GB, Pal SC. Occurrence and significance of Cryptosporidium infection in Calcutta. Trans R Soc Trop Med Hyg. 1989 Jul-Aug; 83(4):520-1. doi: 10.1016/0035-9203(89)90274-5. PubMed PMID: 2617603.

91. Pal S, Taylor HR, Prendergast RA, Whittum-Hudson JA. The antigen specificity of conjunctival lymphocytes during ocular chlamydial infection. Invest. Ophthalmol. Vis. Sci. 1989; 30 (suppl) (467).

92. Chaudhuri PP, Pal S, Pal SC, Das P. Studies in Giardia lamblia trophozoites antigens using Sephacryl S-300 column chromatography, polyacrylamide gel electrophoresis and enzyme linked immunosorbent assay. In Advances in Giardia Research. University of Calgary Press. Calgary. 1988; 191-194.

93. Pal S. Studies on immunological aspects of amebiasis with special reference to its antigenic components. Ph. D thesis, University of Calcutta. 1988; 1-148.

94. Das P, Pal S, Dutta D, Bhattacharya MK, Pal SC. Cryptosporidiosis in Bengali children with acute diarrhoea. Trans R Soc Trop Med Hyg. 1987;81 (2):241. doi: 10.1016/0035-9203(87)90227-6. PubMed PMID: 3617185.

95. Bhattacharya MK, Bhattacharya SK, Das P, Dutta P, Pal S, Mukherjee PP, Chaudhuri AK, Pal SC. Studies in gastric dysfunction in intestinal amoebiasis. Indian J. Physiol. Allied Sci. 1987; 41:36.

96. Das P, Narain L, Dutta GP, Pal S, Pal SC. Improved method of producing amoebic liver abscesses in hamsters for screening of systemically active amoebicides. Aust J Exp Biol Med Sci. 1985 Feb; 63 ( Pt 1):85-9. doi: 10.1038/icb.1985.10. PubMed PMID: 2861806.

97. Nair GB, Chowdhury S, Das P, Pal S, Pal SC. Improved preservation medium for Campylobacter jejuni. J Clin Microbiol.1984 Feb; 19 (2): 298-9. PubMed PMID: 6699154; PubMed Central PMCID: PMC271044.

98. Bhattacharya MK, Pal S, Das P, Bhattacharya SK, Dutta P, Chaudhuri PP, Chaudhuri AK, Pal SC. Profile of intestinal parasites in patients with bowl disorder and gastric dysfunction. Indian J. Publ. Health. 1984; 28:168.

99. Das P, Pal S, Pal SC. Evaluation of the micro enzyme linked immunosorbent assay, indirect hemagglutination, and indirect fluorescence antibody techniques for the serodiagnosis of amoebiasis. J. Diar. Dis. Res. 1984; 2:238-242.

100. Pal S, Das P, Ghose AC, Pal SC. A preliminary report on the excretory-secretory antigen(s) of Entamoeba histolytica. . I.R.C.S Med. Sci. 1984; 12:620-621.

101. Das P, Pal S, Pal SC. Evaluation of the micro enzyme linked immunosorbent assay, indirect hemagglutination, and indirect fluorescence antibody techniques for the serodiagnosis of amoebiasis. J. Diar. Dis. Res. 1984; 2:238-242.
Grants
AI064853 (PI) Neonatal immunity against C. trachomatis infections
AI125885, NIH-NIAD (PI) A sexual transmission-blocking vaccine against Chlamydia infections
Professional Societies
American Society for Microbiology
Chlamydia Basic Research Society
Other Experience
Last updated
09/30/2019